The IL-13 inhibitor class has quickly established itself as a targeted therapeutic strategy for conditions such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps (CRSwNP).

Sangoma will host a conference call on Wednesday, September 17, 2025, at 5:30 pm ET to discuss these results. The dial-in number for the call is 1-833-752-3740 (International +1-647-846-8617).

Bionano Genomics, Inc. (NASDAQ: BNGO) (“Bionano” or the “Company”) today announced the closing of its previously announced public offering of an aggregate of 5,000,000 shares of the Company’s common ...

Robert Redford, who died Tuesday at 89, transformed the film industry with the Sundance Institute and Film Festival.

Welcome to Postmedia’s continuing coverage of the 2025 Calgary civic election. Here’s what’s making news on the campaign ...

GN Group consists of two businesses: hearing instrumentation and audio products/premium gaming gear. While a combination of hearing aids and consumer and professional audio solutions seemingly lacks ...

The Federal Reserve began a two-day meeting on Tuesday, which is expected to result in a rate cut for the first time since ...

Hims & Hers is one of the leading telehealth firms in the US. Since its 2017 launch, the platform has connected patients with healthcare providers across specialties including erectile dysfunction, ...

I rate PAA stock a BUY for patient, long-term dividend investors seeking strong total return potential and resilience amid ...

The University of Evansville (UE) has announced a new interdisciplinary degree, the Bachelor of Science in Integrated ...

Scalefocus has long been a trusted software engineering and innovation partner for businesses across the DACH region, helping them deliver strategic, business-critical initiatives. For clients in ...

Pegasus Tech Ventures, a global venture capital firm headquartered in Silicon Valley, California, and led by Founder and CEO ...